Comparison of Lenvatinib with radiofrequency ablation and radiofrequency ablation alone with radiofrequency ablation planned hepatocellular carcinoma : randomized, prospective, multicenter trial

Lenvatinib - radiofrequency ablation study - Comparison of Lenvatinib with radiofrequency ablation and radiofrequency ablation alone with radiofrequency ablation planned hepatocellular carcinoma : randomized, prospective, multicenter trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000051126

Enrollment

Registered

2023-05-23

Start date

2023-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Lenvatinib 8mg or 12mg daily for 2-4 weeks RFA only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. unresectable hepatocellular carcinoma 2. Child-Pugh score <=7

Exclusion criteria

Exclusion criteria: 1. presence of Microvascular Invasion or extrahepatic spread 2. allergy for Lenvatinib 3. patients refuse to participate in this study 4. physician judged it inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
1. recurrence rate and Time to recurrence / progression (local/ectopic) for target lesion, 2. ablation area for target lesion	—

Countries

Japan

Contacts

Public ContactKento Imajo

SHIN-YURIGAOKA General Hospital Gastroenterology

tera@m-kanazawa.jp044-322-9991

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026